FDA refusal of Stealth Bio drug shows challenges of ultra-rare disease studies

Healthcare

The FDA refused to review Stealth BioTherapeutics’ Barth syndrome drug, telling the company results in a study of just eight patients are insufficient to support its submission. The impasse highlights the challenges of testing drugs for ultra-rare diseases. Barth is so rare that Stealth is unsure it can recruit patients to run a new study.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.